Accolade Q3 2024 Earnings Report
Key Takeaways
Accolade announced financial results for the fiscal third quarter ended November 30, 2023. The company exceeded both top and bottom line guidance and is raising its guidance for fiscal year 2024. They are affirming their expectation for approximately 20% revenue growth and Adjusted EBITDA between 2% - 4% in fiscal year 2025.
Accolade continues to define the future of how healthcare should be experienced.
The company's combination of people and technology is creating a new model for improving health outcomes.
Accolade is closing the physician gap, improving access to care, and leveraging AI and other innovations.
Accolade plans to deliver positive Adjusted EBITDA in the fourth quarter and next fiscal year.
Accolade
Accolade
Forward Guidance
Accolade provides forward-looking guidance on revenue and Adjusted EBITDA. For the fiscal fourth quarter ending February 29, 2024, they expect revenue between $121.5 million and $125.5 million and Adjusted EBITDA between $16 million and $20 million. For the fiscal year ending February 29, 2024, they expect revenue between $411 million and $415 million and Adjusted EBITDA between $(6) million and $(10) million. For the fiscal year ending February 28, 2025, they are affirming preliminary revenue guidance of approximately 20% growth and Adjusted EBITDA between 2% and 4% of revenue.
Positive Outlook
- Revenue between $121.5 million and $125.5 million for the fiscal fourth quarter ending February 29, 2024.
- Adjusted EBITDA between $16 million and $20 million for the fiscal fourth quarter ending February 29, 2024.
- Revenue between $411 million and $415 million for the fiscal year ending February 29, 2024.
- Adjusted EBITDA between $(6) million and $(10) million for the fiscal year ending February 29, 2024.
- Revenue growth of approximately 20% for the fiscal year ending February 28, 2025.